# 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

> **NCT03173924** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 96 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Prostatic Neoplasms
- Prostate Cancer
- Prostatic Cancer
- Prostate Neoplasms

## Interventions

- **DRUG:** 18F-NaF
- **DRUG:** 18F-DCFPyL
- **DRUG:** 18F-FDG

## Key facts

- **NCT ID:** NCT03173924
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-06
- **Primary completion:** 2028-02-06
- **Final completion:** 2028-02-06
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173924, "18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03173924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*